[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,69,97,129,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640305","effect-of-low-dose-galactose-on-glycaemia-and-glucose-kinetics-100640305",false,"NCT07599683","Effect of Low Dose Galactose on Glycaemia and Glucose Kinetics","EFFECT OF LOW DOSE GALACTOSE ON GLYCAEMIA AND GLUCOSE KINETICS","GLOWS","Inclusion Criteria:\n\n* Age: 18 years and above;\n* Normoglycaemic (fasting glucose \\\u003C6.1 mmol\u002FL)\n* Body mass index: 18.5-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* weight instability (\\>5% change within last 3 months);\n* pregnant or lactating;\n* following a very low-carbohydrate (ketogenic) diet;\n* diagnosis of diabetes or prediabetes, or any other metabolic disease;\n* dietary intolerances or allergies, or to any other study procedures;\n* disorders in the ability to metabolise galactose or fructose (e.g., galactosemias);\n* diagnosis of any gastrointestinal disorders;\n* any other condition\u002Fmedications that could introduce bias;\n* unable to understand and follow study procedures",true,"ALL","18 Years",{"count":21,"type":22},25,"ESTIMATED","INTERVENTIONAL",[25],"NA","This project will establish the degree to which adding low-dose galactose to a meal can control blood sugar levels. People will consume standardised glucose drinks (75g glucose, as an oral glucose tolerance test). People will consume these with and without the addition of galactose, and with the addition of another sugar (fructose) for an extra comparison. We will use state-of-the-art labelling methods (dual stable isotope technology) to follow what happens to the glucose that is ingested and understand what happens to sugar being released by the liver and sugar being taken up by other tissues like the muscles. These methods can tell us how the addition of galactose can control blood sugar levels. For example, the galactose could slow down the appearance of glucose from the gut and\u002For liver released into the blood, or it could increase the disappearance of glucose from the blood into muscles. We will measure the appearance of our label on exhaled breath, which will establish whether ingested sugar is stored, or burned as fuel. We will also explore other potential ways in which galactose might control blood sugar levels by measuring key hormones and metabolites that contribute to blood sugar control (for example, insulin, fatty acids, and incretin hormones which potentiate insulin secretion). This additional evidence of how galactose can control blood sugar levels will provide the understanding required to best make use of this approach across a variety of settings.",[28],"Glucose","RECRUITING","2026-05-14",{"date":32,"type":33},"2026-05-20","ACTUAL",{"date":35,"type":33},"2026-01-01",{"date":37,"type":22},"2029-12-31",{"name":39,"class":40},"University of Bath","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100574162","comparative-efficacy-of-intra-articular-vs-mri-guided-extra-articular-dextrose-injections-in-knee-osteoarthritis-management-100574162","NCT06755697","Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management","Inclusion Criteria:\n\n1. . age between 45 to 80 years old;\n2. . meet at least three of the six American College of Rheumatology (ACR) criteria, including age over 50 years, morning stiffness less than 30 minutes, crepitus in passive knee movements, bony tenderness, bony enlargement, and no palpable warmth;\n3. . radiologic grading of 2 or 3 according to Kellgren-Lawrence criteria;\n4. showing willingness to receive prolotherapy.\n\nExclusion Criteria:\n\n1. . severe systemic disorders including cancer, uncontrolled diabetes mellitus, sepsis, or cardiopulmonary diseases;\n2. . history of anticoagulation therapy, knee injection over the past three months;\n3. . history of knee surgery or candidates for knee arthroplasty;\n4. . history of drug abuse;\n5. . a history of intolerance to prolotherapy;\n6. . pregnancy;\n7. . infectious arthritis, inflammatory joint diseases, joint dysplasia;\n8. Body Mass Index (BMI) greater than 35 kg\u002Fm2;\n9. . not suitable or no willing to received MRI examination of the knee.","45 Years","80 Years",{"count":51,"type":22},60,[25],"Osteoarthritis (OA) is a serious worldwide public health concern, causing increased disability-adjusted life years (DALY), the reasons of which include rising prevalence of obesity and increasing older populations. The knee is one of the most easily injured joint in the body, and knee OA can become a chronic and disabling condition that pose a threat to not only the patient but also his or her caretakers and healthcare resources. The prevalence of knee OA is 5% - 15% in men over 60 years, and 10% - 25% in women aged more than 60.\n\nKnee OA can result from injuries, diseases, or wear and tear from overuse. It refers to structural changes that affect subchondral bone, articular cartilage, menisci, ligaments, synovium, and other joint structures. Currently, there are several conservative management of knee OA, including physiotherapy (therapeutic exercise, diathermy, electrotherapy), oral or topical medications, intra-articular and extra-articular injections, and radiofrequency.\n\nThere are various substances used in injections for knee OA, among which are corticosteroid, platelet-rich plasma (PRP), AmnioFix, exosome, dextrose, and hyaluronic acid (HA). Compared with PRP, AmnioFix, exosome, and HA, which are not covered by the health insurance system, dextrose is a readily available and cost-effective substance. The principle of hypertonic dextrose injection, \"prolotherapy\", is injection of small volumes of the irritant solution at or around the lesion in order to stimulate fibroblast and vascular proliferation, local tissue healing, reduction of joint instability, thus resulting in pain relief. Previous studies have demonstrated that prolotherapy resulted in clinically meaningful sustained improvement of function and pain in knee OA, and there were no severe adverse events related to hypertonic dextrose injection. A study in 2023 showed that among various dextrose concentrations, higher concentrations demonstrated greater improvement of knee OA, thus 20% dextrose is recommended.\n\nRegarding the site of dextrose injection in knee OA, previous studies demonstrated comparable effects of intra-articular and extra-articular injections. The periarticular injections include points around the knee where periarticular nerves exit the joint capsule, and acupuncture points at upper medial and lateral parts of knee joint. A study in 2024 revealed that prolotherapy combining intra-articular with peri-articular perineural injection resulted in better pain alleviation and improvement in knee joint function in knee OA. There are several choices of imaging modality for recognizing the sites of lesion in knee OA, such as X-ray, ultrasound (US), and magnetic resonance imaging (MRI). Radiography is used to assess osteophytes, joint space narrowing, and subchondral sclerosis, but it has limited ability to detect synovial inflammation, joint effusion, soft tissue abnormalities, and early cartilage damage. US can be used to evaluate synovial fluid and cartilage thickness, but not deep structures (e.g. subchondral bone change, meniscus tear, and ACL tear, etc.). On the other hand, MRI is an optimal and accurate imaging choice for visualizing soft tissue as well as deep structures (e.g. ACL, meniscus, etc) in knee OA. The MRI findings of knee OA includes cartilage damage, meniscus tear, bone marrow lesions, synovitis, ligamentous laxity, and osteophytes. The detection of bony lesions can aid intraosseous Infiltrations, and signs of ligamentous laxity also provides target for ligaments injection. However, there is no current evidence on the effectiveness of prolotherapy targeting knee OA lesion sites according to MRI findings.\n\nBecause the effectiveness of prolotherapy targeting lesion sites according to MRI findings has not been well established, the investigators aim to investigate whether injecting dextrose into MRI-positive lesion sites is more beneficial for knee OA comparing to intra-articular injections. The investigators hypothesize that MRI could be a good choice for the guidance of prolotherapy targets.",[55,28,56,57,58,59],"Knee Osteoarthritis","Prolotherapy","MRI","Physical Therapy","Rehabilitation","2026-04-21",{"date":62,"type":33},"2026-04-24",{"date":64,"type":33},"2025-01-23",{"date":66,"type":22},"2028-12-31",{"name":68,"class":40},"Shin Kong Wu Ho-Su Memorial Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100466406","breaking-up-prolonged-sedentary-behavior-to-improve-cardiometabolic-health-100466406","NCT05353322","Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health","Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health: An Adaptive Dose-Finding Study","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to read, write and speak English or Spanish\n* Limited or no chronic medical conditions \\[examples include but not limited to: CVD, diabetes, chronic obstructive pulmonary disease (COPD), HIV\u002FAIDS; participants with high blood pressure\u002Fhypertension and\u002For high cholesterol\u002Fhyperlipidemia may be included if they are currently prescribed and taking medication for these conditions\\]\n* Do not take medication (over-the-counter or herbal) to control glucose (such as a diabetes control medication)\n* Not currently pregnant\n* Do not currently smoke cigarettes\n* No pre-existing musculoskeletal conditions (including but not limited to osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis) that would prevent participation in intermittent physical activity\n* No allergies to common food allergens including wheat, eggs, milk or other dairy, gluten, fructose, peanuts or other nuts\n* No dietary restrictions such as vegan, gluten free, halal\n\nExclusion Criteria:\n\n• Unable to provide consent",{"count":77,"type":22},324,[25],"The purpose of this Phase 1 research study is to answer two questions: (1) How frequent should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? To address these questions, this project will conduct a state-of-the-art adaptive dose finding study under controlled laboratory conditions to determine the minimally effective dose (the smallest dose) that yields cardiometabolic benefit for two separate sedentary break elements (frequency and duration). Study findings will ultimately determine how often and for how long people should break up periods of prolonged sedentary time to transiently improve established cardiovascular risk factors; key foundational information critical to the success of future long-term trials and ultimately public health guidelines.\n\nPrimary Aim: To determine the minimally effective dose combination(s) of frequency and duration needed to provide cardiometabolic benefit during an 8-hour experimentation period. Specifically, the study will determine:\n\n1a. For each fixed duration, the minimum sedentary break frequency (e.g., every 30 min, 60 min, 120 min) that demonstrates a reduction in systolic BP, diastolic BP, or glucose compared with a sedentary control condition.\n\n1b. For each fixed frequency, the minimum sedentary break duration (e.g., activity breaks of 1 min, 5 min, 10 min) that demonstrates a reduction in systolic BP, diastolic BP, or glucose compared with a sedentary control.\n\nSecondary Aim: It is also critical to public health strategy to assess the acceptability\u002Ffeasibility of various sedentary break doses as too high a dose will yield poor uptake. To address this need, the maximally tolerated dose (the highest dose that does not cause undue physical\u002Fpsychological distress) for frequency and duration of sedentary breaks will also be determined via assessment of 4 constructs: physical exhaustion\u002Ffatigue, affect (e.g., mood, emotion), tolerability (e.g., completion of dose protocol), and safety (e.g., hypoglycemia). Maximally tolerated dose will be defined as the highest dose where \\\u003C20% of participants exhibit an adverse outcome.",[81,82,83,28],"Sedentary Behavior","Cardiometabolic Risk Factors","Blood Pressure",[81,85,83,28,86,87],"Physical Activity","Insulin","Dose-finding","2026-04-06",{"date":90,"type":33},"2026-04-09",{"date":92,"type":33},"2022-06-30",{"date":94,"type":22},"2028-03-31",{"name":96,"class":40},"Columbia University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100628404","timing-of-broccoli-sprout-intake-to-improve-exercise-performance-100628404","NCT07461194","Timing of Broccoli Sprout Intake to Improve Exercise Performance","Effects of Acute and Subacute Intake of Broccoli Sprouts Intake on Exercise Performance and Recovery","Inclusion Criteria:\n\nHealthy, endurance-trained adults aged 18-64 years.\n\nRegular endurance training (e.g., cycling\u002Frunning) and ability to complete a standardized 2-hour high-intensity cycling session on an ergometer.\n\nApproved health declaration and screening assessment by study staff (including that ergometer testing can be performed safely).\n\nWilling and able to follow the study protocol (diet\u002Ffasting instructions, standardized training before visits, attendance at all four laboratory visits).\n\nNo known allergy\u002Fhypersensitivity to ingredients in the broccoli sprout drink or placebo drink.\n\nExclusion Criteria:\n\nDoes not meet inclusion criteria at screening (e.g., abnormal health declaration or medical findings making intense endurance exercise or muscle biopsy inappropriate).\n\nKnown allergy\u002Fhypersensitivity to ingredients in the intervention or placebo drink (broccoli\u002Fcruciferous vegetables or alfalfa) or other relevant food allergy.\n\nOngoing illness, fever, or infection at any test occasion, or other acute medical event judged to affect safety or data quality.\n\nOngoing treatment with medications\u002Fsupplements judged to affect primary outcomes or increase risk (e.g., anti-inflammatory medication close to test days per study instructions).\n\nPregnancy (if women are included) or breastfeeding.\n\nInability to comply with the study protocol (e.g., failure to standardize diet\u002Ffasting, deviating training\u002Falcohol intake despite instructions, or repeated missed visits).\n\nParticipant withdraws consent or investigator judges continued participation to pose risk.\n\n\\-","50 Years",{"count":106,"type":22},30,[25],"This study examines how the timing of intake of a broccoli sprout-based drink (a natural source of isothiocyanates, ITCs) affects physiological responses, recovery, and performance after a standardized endurance cycling session. Healthy, endurance-trained adults (18-64 years) will complete four laboratory visits at the Swedish School of Sport and Health Sciences (GIH): one screening\u002Fphysiology test visit and three intervention visits in a randomized, double-blind, placebo-controlled cross-over design. On intervention visits, participants will ingest either an active broccoli sprout drink (50 g sprouts) or a placebo drink based on alfalfa sprouts (50 g sprouts) according to randomization. The drink will be consumed either approximately 16 hours before exercise (the evening before) or approximately 3 hours before exercise (the morning of the test), enabling comparison of timing in relation to a standardized \\~2-hour cycling protocol (individualized intensity) followed by a 10 km cycling time trial. Outcomes include measures of performance, heart rate, perceived exertion and recovery, blood glucose and lactate, and metabolic responses. Venous blood samples are collected at multiple time points before and after exercise and during the subsequent laboratory recovery period, and muscle biopsies are obtained at defined time points to assess muscle metabolism and recovery-related markers. Participants return \\~24 hours after exercise for follow-up sampling after an overnight fast, including a glucose tolerance test",[110,28,111,112,113,114],"Physical Performance","Glycogen Metabolism","Lactate","Broccoli Sprout","Isothiocyanate",[116,112,117,118,114],"Broccoli Sprouts","Exercise","Glycogen","NOT_YET_RECRUITING","2026-03-04",{"date":122,"type":33},"2026-03-10",{"date":124,"type":22},"2026-03-31",{"date":126,"type":22},"2028-09-01",{"name":128,"class":40},"The Swedish School of Sport and Health Sciences",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100587637","tracing-of-real-time-glu13cose-metabolism-in-human-immune-cells-100587637","NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells","TORCH","Inclusion Criteria:\n\n* Adults aged 18 or older\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner or in police custody\n* Uncontrolled hyperglycemia\u002Fdiabetes\n* Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period\n* Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives\n* Any reason which, in the opinion of the study investigator, adds additional risk to the participant",{"count":137,"type":22},12,[25],"The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.",[28,141,142,143],"Metabolism","Isotope Labeling","Immune System and Related Disorders","2025-11-01",{"date":146,"type":33},"2025-11-04",{"date":148,"type":33},"2025-10-01",{"date":150,"type":22},"2027-06-30",{"name":152,"class":40},"Vanderbilt University Medical Center",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":41},"100512893","assessing-the-value-of-avocados-on-glycemic-control-in-type-2-diabetes-100512893","NCT05958368","Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes","The Effects of Hass Avocados on Glycemic Control in Persons With Type 2 Diabetes: A Randomized Controlled Crossover Trial","AVOCADO-T2D","Inclusion Criteria:\n\n* Participant reported diagnosis of Type 2 diabetes\n* HbA1c between 5.7%-11% (inclusive) and \u002F or fasting blood glucose of ≥ 100 mg\u002FdL\n* BMI 27-50 kg\u002Fm2 (inclusive)\n* Age range - 18 - 65 years (inclusive)\n* On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)\n* Willing to follow all requirements of study protocol including blood draws\n* Under the care of a physician who will be responsible for managing the subject's diabetes\n* Willing to give release to provide their treating MD with information about the trial\n\nExclusion Criteria:\n\n* Not willing or unable to consume study foods including avocados\n* Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months\n* Taking prescription or OTC weight loss medications within last 4 weeks\n* History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)\n* History of major surgery within three months of enrollment\n* Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)\n* Renal insufficiency consisting of potassium over 5.5 (mmol\u002FL) on a non-hemolyzed specimen, or a creatinine over 2.5 mg\u002FdL\n* Bilirubin over 3 (mg\u002FdL) or an albumin less than 3 (g\u002FdL)\n* ALT \\> 3 (IU\u002FL) times the upper limit of normal (normal range is 7-56)\n* Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.\n* Those on higher doses of diuretics (furosemide 40mg or higher or comparable)\n* Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)\n* Presence of implanted cardiac defibrillator\n* Blood pressure ≥180\u002F100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.\n* Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable\n* Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease\n* Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.\n* Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)\n* Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control\n* Currently consuming \\>14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation\n* Participation in another clinical trial within 30 days prior to enrollment\n* Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial","65 Years",{"count":163,"type":22},48,[25],"The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.",[167,86,168,169,28,170],"Diabetes Mellitus, Type 2","Fructosamine","C-Reactive Protein","Overweight and Obesity","2025-07-28",{"date":173,"type":33},"2025-07-31",{"date":175,"type":33},"2023-10-10",{"date":177,"type":22},"2026-12-15",{"name":179,"class":40},"Pennington Biomedical Research Center"]